or Try an Advanced Search...

    Hepatitis C Virus Stocks List

    Symbol Grade Name % Change
    IONS B Ionis Pharmaceuticals, Inc. 1.02
    VRTX B Vertex Pharmaceuticals Incorporated -0.74
    ENTA C Enanta Pharmaceuticals, Inc. -2.30
    ABBV C AbbVie Inc. -1.28
    INO D Inovio Pharmaceuticals, Inc. -1.19
    SCYX D SCYNEXIS, Inc. -0.51
    NNVC D NanoViricides, Inc. -1.12
    RGLS D Regulus Therapeutics Inc. 2.27
    BMY F Bristol-Myers Squibb Company -0.96
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Hepatitis C Hepatitis B Hepatitis B Virus Infection Hepatitis C Virus Infection Immunodeficiency Infectious Diseases Influenza Medicine S&P 500 Autoimmune Disease Biopharmaceutical Cancer Chemical Compounds Coronavirus Cyclophilin Cyclopropanes Depressive Disorder Diabetes Dystrophy

    Related ETFs - A few ETFs which own one or more of the above listed Hepatitis C Virus stocks.

    Symbol Grade Name Weight
    FTXH C First Trust Nasdaq Pharmaceuticals ETF 17.53
    MEDX B Horizon Kinetics Medical ETF 11.58
    MEDI D Harbor Health Care ETF 10.38
    BOTZ C Global X Robotics & Artificial Intelligence Thematic ETF 10.01
    PPH B Market Vectors Pharmaceutical ETF 9.97
    View all Hepatitis C Virus ETFs...
    Compare ETFs
    Compare FTXH to MEDX Compare MEDI to PPH Compare MEDX to PPH

        Hepatitis C Virus Stocks Recent News

        Date Stock Title
        Jul 3 ABBV AbbVie Q2 IPR&D expenses to lower EPS by $0.52
        Jul 3 ABBV Company News for Jul 3, 2024
        Jul 3 ABBV AbbVie: A Hold Again (Rating Downgrade)
        Jul 2 INO INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer
        Jul 2 VRTX Vertex’s cystic fibrosis drug gets FDA priority review
        Jul 2 VRTX Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
        Jul 2 ABBV With 72% ownership, AbbVie Inc. (NYSE:ABBV) boasts of strong institutional backing
        Jul 2 ABBV AbbVie to Host Second-Quarter 2024 Earnings Conference Call
        Jul 2 BMY Eisai and Bristol Myers Squibb terminate ADC development deal
        Jul 1 VRTX Vertex to Announce Second Quarter 2024 Financial Results on August 1
        Jul 1 BMY Eisai receives rights to antibody drug conjugate after Bristol ends collaboration
        Jul 1 BMY What the Options Market Tells Us About Bristol-Myers Squibb
        Jul 1 BMY Bristol-Myers Squibb to Pay $2.7 Million to Settle Potential Anti-Competition Case, Israeli Agency Says
        Jul 1 ABBV 2 High-Yielding Healthcare Stocks to Buy With $1,000 in July
        Jul 1 VRTX Bull Market Buys: 2 Growth Stocks to Own for the Long Run
        Jul 1 ABBV AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
        Jul 1 ABBV AbbVie names Robert A. Michael to CEO role
        Jul 1 INO Inovio Pharmaceuticals added to Russell 2000 index effective July 1
        Jul 1 BMY Bristol Myers to pay $2.7 million to settle Israel anti-competition charges
        Jul 1 ABBV Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
        Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Hepatitis C Hepatitis B Hepatitis B Virus Infection Hepatitis C Virus Infection Immunodeficiency Infectious Diseases Influenza Medicine S&P 500 Autoimmune Disease Biopharmaceutical Cancer Chemical Compounds Coronavirus Cyclophilin Cyclopropanes Depressive Disorder Diabetes Dystrophy
        Hepatitis C Virus

        Hepatitis C virus (HCV) is a small (55–65 nm in size), enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. Hepatitis C virus is the cause of hepatitis C and some cancers such as liver cancer (hepatocellular carcinoma, abbreviated HCC) and lymphomas in humans.

        More about Hepatitis C Virus
        Browse All Tags